Recent investigations have focused on the intersection of GLP-1|GIP|GCGR agonist therapies and dopamine communication. While GCGR agonists are increasingly employed for managing type 2 T2DM, their potential impacts on https://rajankbga268699.livebloggs.com/48372467/new-gcgr-stimulators-and-dopamine-modulation-a-contextual-copyrightination